Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.

Prill S, Caddeo A, Baselli G, Jamialahmadi O, Dongiovanni P, Rametta R, Kanebratt KP, Pujia A, Pingitore P, Mancina RM, Lindén D, Whatling C, Janefeldt A, Kozyra M, Ingelman-Sundberg M, Valenti L, Andersson TB, Romeo S.

Sci Rep. 2019 Aug 12;9(1):11585. doi: 10.1038/s41598-019-47737-w.

2.

PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report.

Pirazzi C, Tavaglione F, Tivesten Å, Romeo S.

J Endocr Soc. 2019 Jun 6;3(8):1461-1464. doi: 10.1210/js.2019-00070. eCollection 2019 Aug 1.

3.

Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels.

Pavanello C, Pirazzi C, Bjorkman K, Sandstedt J, Tarlarini C, Mosca L, Romeo S, Calabresi L, Mancina RM.

J Clin Lipidol. 2019 Sep - Oct;13(5):778-787.e6. doi: 10.1016/j.jacl.2019.06.011. Epub 2019 Jul 4.

4.

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;:. Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.

PMID:
31272931
5.

A benchmark-driven approach to reconstruct metabolic networks for studying cancer metabolism.

Jamialahmadi O, Hashemi-Najafabadi S, Motamedian E, Romeo S, Bagheri F.

PLoS Comput Biol. 2019 Apr 22;15(4):e1006936. doi: 10.1371/journal.pcbi.1006936. eCollection 2019 Apr.

6.

Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis.

Pingitore P, Sasidharan K, Ekstrand M, Prill S, Lindén D, Romeo S.

Int J Mol Sci. 2019 Apr 2;20(7). pii: E1629. doi: 10.3390/ijms20071629.

7.

MBOAT7 is anchored to endomembranes by six transmembrane domains.

Caddeo A, Jamialahmadi O, Solinas G, Pujia A, Mancina RM, Pingitore P, Romeo S.

J Struct Biol. 2019 Jun 1;206(3):349-360. doi: 10.1016/j.jsb.2019.04.006. Epub 2019 Apr 5.

8.

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients.

Dongiovanni P, Meroni M, Baselli G, Mancina RM, Ruscica M, Longo M, Rametta R, Cespiati A, Pelusi S, Ferri N, Ranzani V, Nobili V, Pihlajamaki J, Fracanzani AL, Badiali S, Petta S, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Lipid Res. 2019 Jun;60(6):1144-1153. doi: 10.1194/jlr.P090449. Epub 2019 Mar 27.

PMID:
30918065
9.

Don't forget to ask how mum and dad are doing.

Romeo S.

Liver Int. 2019 Apr;39(4):623-624. doi: 10.1111/liv.13984. No abstract available.

PMID:
30916862
10.

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC.

Sci Rep. 2019 Mar 6;9(1):3682. doi: 10.1038/s41598-019-39998-2.

11.

Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.

Lindén D, Ahnmark A, Pingitore P, Ciociola E, Ahlstedt I, Andréasson AC, Sasidharan K, Madeyski-Bengtson K, Zurek M, Mancina RM, Lindblom A, Bjursell M, Böttcher G, Ståhlman M, Bohlooly-Y M, Haynes WG, Carlsson B, Graham M, Lee R, Murray S, Valenti L, Bhanot S, Åkerblad P, Romeo S.

Mol Metab. 2019 Apr;22:49-61. doi: 10.1016/j.molmet.2019.01.013. Epub 2019 Feb 5.

12.

Notch and Nonalcoholic Fatty Liver and Fibrosis.

Romeo S.

N Engl J Med. 2019 Feb 14;380(7):681-683. doi: 10.1056/NEJMcibr1815636. No abstract available.

PMID:
30763194
13.

Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.

Santos RD, Valenti L, Romeo S.

Atherosclerosis. 2019 Mar;282:110-120. doi: 10.1016/j.atherosclerosis.2019.01.029. Epub 2019 Jan 30. Review.

PMID:
30731283
14.

Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases.

Spagnuolo R, Montalcini T, De Bonis D, Ferro Y, Cosco C, Mazza E, Romeo S, Doldo P, Pujia A.

Nutrients. 2019 Feb 1;11(2). pii: E303. doi: 10.3390/nu11020303.

15.

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6. doi: 10.1016/j.cgh.2019.01.027. Epub 2019 Jan 29.

PMID:
30708111
16.

Lipid Oxidation Assessed by Indirect Calorimetry Predicts Metabolic Syndrome and Type 2 Diabetes.

Pujia A, Mazza E, Ferro Y, Gazzaruso C, Coppola A, Doldo P, Grembiale RD, Pujia R, Romeo S, Montalcini T.

Front Endocrinol (Lausanne). 2019 Jan 10;9:806. doi: 10.3389/fendo.2018.00806. eCollection 2018.

17.

Deciphering the role of V200A and N291S mutations leading to LPL deficiency.

Botta M, Maurer E, Ruscica M, Romeo S, Stulnig TM, Pingitore P.

Atherosclerosis. 2019 Mar;282:45-51. doi: 10.1016/j.atherosclerosis.2019.01.004. Epub 2019 Jan 20.

18.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators.

N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.

PMID:
30403574
19.

Bergamot Polyphenol Fraction Exerts Effects on Bone Biology by Activating ERK 1/2 and Wnt/β-Catenin Pathway and Regulating Bone Biomarkers in Bone Cell Cultures.

Pujia A, Russo C, Maurotti S, Pujia R, Mollace V, Romeo S, Montalcini T.

Nutrients. 2018 Sep 14;10(9). pii: E1305. doi: 10.3390/nu10091305.

20.

The role of PNPLA3 in health and disease.

Pingitore P, Romeo S.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun;1864(6):900-906. doi: 10.1016/j.bbalip.2018.06.018. Epub 2018 Jun 20. Review.

PMID:
29935383

Supplemental Content

Loading ...
Support Center